NCT05153434Phase 2Completed

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Study sponsor: Aardvark Therapeutics, Inc. · AARD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-09-24Actual

Enrollment · participants19Actual

Source updated2026-09-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-02 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Incidence of Treatment-Emergent Adverse Events (TEAE)

+ Updated value

measure: Incidence of Treatment Emergent Adverse Events (TEAE)

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Prader-Willi Syndrome

Treatments or interventions studied

ARD-101Drug

Primary outcomes · main study measures

Read the study measures

measure: Incidence of Treatment Emergent Adverse Events (TEAE); description: The incidence of treatment emergent adverse events (TEAE) reported through the 28 days of treatment and the 14 days post treatment phase. TEAEs were those events occurring after treatment began.; timeFrame: Adverse Events were collected from time of informed consent through end of study; approximately 70 days (28 days of screening, 28 days of treatment, 14 days post treatment follow up).

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history